UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report

(Date of earliest event reported)

October 2, 2013

 

 

CELATOR PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   000-54852   20-2680869

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

200 PrincetonSouth Corporate Center, Suite 180

Ewing, New Jersey

  08628
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (609) 243-0123

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.07. Submission of Matters to a Vote of Security Holders.

We held our 2013 Annual Meeting of Stockholders on October 2, 2013. The following are the voting results for each matter voted upon:

Proposal 1: The election of the following nominees as directors of the company to serve until the next annual election of directors by the company’s stockholders.

 

Name of Director Nominee

   Votes For      Votes Withheld      Broker Non-Votes  

Joseph A. Mollica

     15,114,058         54         —     

Michael R. Dougherty

     15,114,112         —           —     

Scott T. Jackson

     15,114,058         54         —     

Richard S. Kollender

     15,114,112         —           —     

Scott Morenstein

     15,114,112         —           —     

Nicole Vitullo

     15,114,112         —           —     

Proposal 2: The ratification of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2013.

 

For

  

Against

    

Abstain

 
15,080,409      —           33,703   

 

-2-


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

CELATOR PHARMACEUTICALS, INC.
By:  

/s/ Fred M. Powell

  Fred M. Powell,
  Vice President and Chief Financial Officer

Date: October 4, 2013

 

-3-